Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia

This study has been terminated.
(Study terminated as principal investigator [PI] left the university.)
Information provided by:
Masonic Cancer Center, University of Minnesota Identifier:
First received: July 5, 2000
Last updated: May 25, 2011
Last verified: May 2011
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2005
  Primary Completion Date: September 2005 (Final data collection date for primary outcome measure)